Brainstorm cell therapeutics reaches alignment with fda on cmc aspects of phase 3b nurown® clinical trial

New york , june 26, 2024 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced it has reached alignment with the u.s. food and drug administration (fda) on the chemistry, manufacturing, and controls (cmc) aspects of brainstorm's phase 3b clinical trial for nurown®, its investigational therapy for amyotrophic lateral sclerosis (als).     this type c meeting builds upon the positive momentum established in april 2024, when the fda granted brainstorm a special protocol assessment (spa) agreement for its nurown phase 3b trial.
BCLI Ratings Summary
BCLI Quant Ranking